Mevacor OTC Study Shows High-Risk Users Will “Upstream,” Merck Says
This article was originally published in The Tan Sheet
Executive Summary
Merck's educational strategy for potential over-the counter sale of 20 mg Mevacor (lovastatin) will prevent rather than increase undertreatment among people who should be using more aggressive statin therapy, the firm contends
You may also be interested in...
Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
The top three statins - Zocor, Lipitor, and Pravachol -have roughly equivalent low risks of rhabdomyolysis, according to a study of health plan prescription data released by the Journal of the American Medical Association Nov. 23
Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
The top three statins - Zocor, Lipitor, and Pravachol -have roughly equivalent low risks of rhabdomyolysis, according to a study of health plan prescription data released by the Journal of the American Medical Association Nov. 23
Top Statins Have Equally Low Rhabdomyolysis Risk, Says Graham In JAMA
The top three statins - Zocor, Lipitor, and Pravachol -have roughly equivalent low risks of rhabdomyolysis, according to a study of health plan prescription data released by the Journal of the American Medical Association Nov. 23